



This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**



1. (Currently Amended) A The synthetic peptide of general formula I



~~in which~~

~~Y<sup>1</sup>— is Phe, Lys, Cys and Orn, and~~

~~Y<sup>2</sup>— is Asp, Cys and Glu, and Y<sup>1</sup> also has the meaning of Y<sup>2</sup>, and Y<sup>2</sup> has the meaning of Y<sup>1</sup>,~~



wherein Y<sup>1</sup> and Y<sup>2</sup> are linked to one another the Lys in 1-position is linked with the Asp in 13-position via a side chain or a  $\beta$ -turn mimetic agent, and

~~X<sup>1-14</sup> represents any amino acid, which can be connected to one another via side chains.~~

- 2-6. (Canceled)

7. (Currently Amended) A The synthetic peptide of general formula

~~I, according to claim 1, of the structures~~

Lys-Ile-Ser-Val-Ser-Tyr-Asn-Phe-Ala-Leu-Val-Asp-D-Tyr

1 2 3 4 5 6 7 8 9 10 11 12 13 14

Leu-Val-Phe-Glu-Arg-Thr-Lys-Ser-Asp-Thr-Asp,

15 16 17 18 19 20 21 22 23 24 25

wherein the Lys in 1-position is linked with the Asp in 13-position via a side chain,

~~Lys-Ile-Ser-Val-Ser-Tyr-Glu-Asn-Phe-Ala-Leu-Val-Asp-D-Tyr~~

~~1 2 3 4 5 6 7 8 9 10 11 12 13 14~~

~~Leu-Val-Phe-Glu-Lys-Thr-Lys-Ser-Asp-Thr-Asp,~~

~~15 16 17 18 19 20 21 22 23 24 25~~

~~wherein the Lys in 1 position is linked with the Asp in 13 position, and Glu in 7 position is linked with Lys in 19 position via a side chain, and~~

~~Lys-Ile-Ser-Val-Ser-Tyr-Glu-Asn-Phe-Ala-Leu-Val-Asp-D-Tyr~~

~~1 2 3 4 5 6 7 8 9 10 11 12 13 14~~

~~Leu-Val-Phe-Glu-Lys-Thr-Lys-Ser-Asp-Thr-Asp,~~

~~15 16 17 18 19 20 21 22 23 24 25~~

8. (Canceled)

9. (Currently Amended) A pharmaceutical composition comprising a the peptide according to claim 1 and a, ~~and at least one pharmaceutically acceptable carrier suitable solution or vehicle.~~

10. (Currently Amended) The composition of claim 9, which ~~wherein said composition~~ is in a form suitable for intravenous, subcutaneous, oral or transdermal administration.

11. (Previously Presented) A method for treating or preventing thrombosis, unstable angina, arteriosclerosis, reocclusion of a vessel after PTCA/PTA, reocclusion of a vessel after thrombolysis for treating a myocardial infarction, or blood clotting comprising administering to a patient in need thereof a therapeutically effective amount of a peptide of claim 1.

12-17. (Cancelled)

18. (New) A pharmaceutical composition comprising the peptide according to claim 7 and a pharmaceutically acceptable carrier.

19. (New) The composition of claim 18, which is in a form suitable for intravenous, subcutaneous, oral or transdermal administration.

20. (New) A method for treating or preventing thrombosis, unstable angina, arteriosclerosis, reocclusion of a vessel after PTCA/PTA, reocclusion of a vessel after thrombolysis for treating a myocardial infarction, or blood clotting comprising administering to a patient in need thereof a therapeutically effective amount of a peptide of claim 7.

21. (New) A method according to claim 11, wherein thrombosis is treated or prevented.

22. (New) A method according to claim 11, wherein unstable angina is treated or prevented.
23. (New) A method according to claim 11, wherein arteriosclerosis is treated or prevented.
24. (New) A method according to claim 11, wherein reocclusion of a vessel after PTCA/PTA is treated or prevented.
25. (New) A method according to claim 11, wherein reocclusion of a vessel after thrombolysis for treating a myocardial infarction is treated or prevented.
26. (New) A method according to claim 11, wherein blood clotting is treated or prevented.
27. (New) A method according to claim 20, wherein thrombosis is treated or prevented.
28. (New) A method according to claim 20, wherein unstable angina is treated or prevented.
29. (New) A method according to claim 20, wherein arteriosclerosis is treated or prevented.
30. (New) A method according to claim 20, wherein reocclusion of a vessel after PTCA/PTA is treated or prevented.
31. (New) A method according to claim 20, wherein reocclusion of a vessel after thrombolysis for treating a myocardial infarction is treated or prevented.

32. (New) A method according to claim 20, wherein blood clotting is treated or prevented.